Diffuse large B-cell lymphoma: open trials in New Zealand

4 open trials have a site in New Zealand. Registry data; only the trial team decides who can take part.

NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Trial Treatment · Phase 2/3 · Merck Sharp & Dohme LLC
Aotearoa Clinical Trials ( Site 0501), Auckland
Registry updated 2026-11-03
NCT06486051
A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
Trial Treatment · Phase 2 · Malaghan Institute of Medical Research
Auckland City Hospital, Auckland · Christchurch Hospital, Christchurch · Wellington Hospital, Newtown
Registry updated 2026-08-07
NCT04332822
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Trial Treatment · Phase 3 · Nordic Lymphoma Group
Auckland City Hospital, Grafton · Wellington Blood and Cancer Centre, Wellington
Registry updated 2024-09-19
NCT04920617
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Trial Treatment · Phase 2 · ImmunoVaccine Technologies, Inc. (IMV Inc.)
North Shore Hospital, Auckland · Palmerston North Hospital, Palmerston North
Registry updated 2023-04-07

This page is not medical advice. Talk to your doctor before contacting a trial.

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)